Getting to ‘No’ fast is more important when you are small
Drug development is a complex business. Historically, less than 8% of product candidates are reported to have made it from Phase I to market. One effective way to mitigate risk is to weed out weak and average product candidates and focus resources on lead products and follow-ons with the best chances of success. This blog looks at helpful strategies to identify winners and losers.